Ascendis Pharma A/S to Post Q2 2022 Earnings of ($0.99) Per Share, SVB Leerink Forecasts (NASDAQ:ASND)

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) – Equities researchers at SVB Leerink increased their Q2 2022 EPS estimates for Ascendis Pharma A/S in a report issued on Wednesday, May 11th. SVB Leerink analyst J. Schwartz now forecasts that the biotechnology company will earn ($0.99) per share for the quarter, up from their prior estimate of ($2.31). SVB Leerink has a “Outperform” rating and a $193.00 price objective on the stock. SVB Leerink also issued estimates for Ascendis Pharma A/S’s Q3 2022 earnings at ($1.21) EPS, Q4 2022 earnings at ($1.40) EPS, FY2022 earnings at ($5.92) EPS, FY2023 earnings at ($7.96) EPS and FY2024 earnings at ($5.29) EPS.

Ascendis Pharma A/S (NASDAQ:ASNDGet Rating) last posted its quarterly earnings data on Wednesday, May 11th. The biotechnology company reported ($2.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.25) by $0.04. Ascendis Pharma A/S had a negative net margin of 3,281.45% and a negative return on equity of 51.08%. During the same period in the prior year, the firm earned ($1.41) EPS.

ASND has been the topic of a number of other reports. Citigroup lowered their price objective on shares of Ascendis Pharma A/S from $187.00 to $158.00 in a report on Thursday. Bank of America upgraded shares of Ascendis Pharma A/S from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $148.00 to $161.00 in a report on Tuesday, March 15th. Wells Fargo & Company lowered their target price on shares of Ascendis Pharma A/S from $190.00 to $176.00 in a report on Thursday. Zacks Investment Research downgraded shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Monday, January 17th. Finally, Cantor Fitzgerald reduced their price objective on shares of Ascendis Pharma A/S from $230.00 to $180.00 in a research report on Thursday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $163.58.

NASDAQ ASND opened at $83.12 on Monday. Ascendis Pharma A/S has a 12-month low of $61.58 and a 12-month high of $178.71. The company has a market capitalization of $4.73 billion, a PE ratio of -8.88 and a beta of 0.86. The firm’s 50 day moving average is $105.91 and its 200-day moving average is $122.24.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Artisan Partners Limited Partnership lifted its position in Ascendis Pharma A/S by 21.1% during the third quarter. Artisan Partners Limited Partnership now owns 7,784,860 shares of the biotechnology company’s stock worth $1,240,829,000 after purchasing an additional 1,355,453 shares during the period. RA Capital Management L.P. raised its stake in Ascendis Pharma A/S by 8.5% during the third quarter. RA Capital Management L.P. now owns 7,387,900 shares of the biotechnology company’s stock worth $1,177,557,000 after acquiring an additional 581,559 shares in the last quarter. Wellington Management Group LLP raised its stake in Ascendis Pharma A/S by 14.9% during the third quarter. Wellington Management Group LLP now owns 3,945,244 shares of the biotechnology company’s stock worth $628,832,000 after acquiring an additional 510,971 shares in the last quarter. Janus Henderson Group PLC raised its stake in Ascendis Pharma A/S by 4.0% during the third quarter. Janus Henderson Group PLC now owns 3,251,667 shares of the biotechnology company’s stock worth $518,306,000 after acquiring an additional 124,496 shares in the last quarter. Finally, Spyglass Capital Management LLC raised its stake in Ascendis Pharma A/S by 22.8% during the third quarter. Spyglass Capital Management LLC now owns 1,378,887 shares of the biotechnology company’s stock worth $219,781,000 after acquiring an additional 256,216 shares in the last quarter.

About Ascendis Pharma A/S (Get Rating)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

Recommended Stories

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.